Jeffrey Mann Purchases 20,000 Shares of Embecta (NASDAQ:EMBC) Stock

Embecta Corp. (NASDAQ:EMBC) insider Jeffrey Mann bought 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were bought at an average cost of $4.99 per share, for a total transaction of $99,800.00. Following the completion of the acquisition, the insider owned 262,915 shares of the company’s stock, valued at $1,311,945.85. This trade represents a 8.23% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Embecta Trading Down 0.2%

Shares of NASDAQ:EMBC opened at $5.10 on Friday. Embecta Corp. has a 12-month low of $2.77 and a 12-month high of $15.55. The company has a market capitalization of $288.97 million, a PE ratio of 3.45 and a beta of 0.81. The business has a 50 day moving average of $3.50 and a two-hundred day moving average of $6.41.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Friday, August 7th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.29. The business had revenue of $271.70 million for the quarter, compared to analysts’ expectations of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The business’s revenue was down 8.1% on a year-over-year basis. During the same quarter last year, the company earned $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Equities research analysts predict that Embecta Corp. will post 1.84 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Thursday, August 27th will be given a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.8%. The ex-dividend date is Thursday, August 27th. Embecta’s dividend payout ratio (DPR) is currently 2.70%.

Embecta News Summary

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: CEO Devdatt Kurdikar, CFO Jacob Elguicze and director Jeffrey Z. Mann collectively purchased 70,000 shares worth approximately $334,200 on August 12. The insider buying could signal that management and the director believe Embecta’s shares are undervalued after their steep decline. SEC insider transaction filing
• Neutral Sentiment: Embecta also disclosed a quarterly dividend of $0.01 per share, or $0.04 annualized, with a yield of roughly 0.8%. The modest payout is unlikely to be a major near-term stock catalyst but may appeal to income-focused investors. Embecta dividend and insider trading report
• Neutral Sentiment: Multiple law firms, including Hagens Berman, Bronstein Gewirtz & Grossman, Kaplan Fox, Faruqi & Faruqi and Rosen, reminded investors that August 17 is the deadline to seek lead-plaintiff status. The notices target investors who purchased EMBC securities between November 25, 2025, and May 4, 2026, and mostly repeat previously reported information. Hagens Berman class action deadline notice
• Negative Sentiment: The underlying securities class action alleges that Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business and issued misleading fiscal 2026 guidance. If the claims gain traction, the company could face legal expenses, reputational damage and further questions about management credibility. The allegations have not been proven in court. Hagens Berman lawsuit alert

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on EMBC shares. Weiss Ratings lowered shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Bank of America reduced their price target on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a report on Monday, May 18th. Zacks Research upgraded Embecta from a “strong sell” rating to a “hold” rating in a research report on Friday, July 17th. Mizuho dropped their price objective on Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Finally, Wall Street Zen cut Embecta from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Three analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Embecta has an average rating of “Reduce” and a consensus target price of $11.00.

Institutional Trading of Embecta

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Brooklyn Investment Group lifted its stake in Embecta by 5.9% in the 4th quarter. Brooklyn Investment Group now owns 19,736 shares of the company’s stock valued at $234,000 after buying an additional 1,098 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Embecta by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock worth $209,000 after buying an additional 1,110 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Embecta by 2.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after acquiring an additional 1,159 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Embecta by 1.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,271 shares of the company’s stock valued at $1,785,000 after acquiring an additional 1,520 shares in the last quarter. Finally, A&I Financial Services LLC lifted its position in shares of Embecta by 2.5% in the fourth quarter. A&I Financial Services LLC now owns 63,542 shares of the company’s stock valued at $755,000 after acquiring an additional 1,556 shares in the last quarter. Hedge funds and other institutional investors own 93.83% of the company’s stock.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.